vs
博士伦健康（BHC）与J.B. Hunt（JBHT）财务数据对比。点击上方公司名可切换其他公司
J.B. Hunt的季度营收约是博士伦健康的1.1倍（$3.1B vs $2.8B），J.B. Hunt净利率更高（5.8% vs -3.7%，领先9.5%），博士伦健康同比增速更快（9.3% vs -1.6%），博士伦健康自由现金流更多（$403.0M vs $251.3M），过去两年博士伦健康的营收复合增速更高（14.0% vs 2.6%）
博士伦健康公司（Bausch Health）是一家业务多元化的北美跨国制药企业，全球总部位于加拿大魁北克省拉瓦尔，美国总部设在新泽西州布里奇沃特。公司专注于胃肠病、肝病、神经科、皮肤科、牙科、医疗美容等领域的药物研发、生产及销售，同时提供品牌药和仿制药产品，业务覆盖全球市场。
J.B.亨特运输服务公司是总部位于美国阿肯色州洛厄尔的运输物流企业，1961年8月10日由约翰尼·布莱恩·亨特与乔内尔·亨特在阿肯色州创立。截至1983年，公司已成为美国第80大卡车运输企业，营收达6.2347亿美元，当时运营550台牵引车、1049辆挂车，拥有约1050名员工。
BHC vs JBHT — 直观对比
营收规模更大
JBHT
是对方的1.1倍
$2.8B
营收增速更快
BHC
高出10.8%
-1.6%
净利率更高
JBHT
高出9.5%
-3.7%
自由现金流更多
BHC
多$151.7M
$251.3M
两年增速更快
BHC
近两年复合增速
2.6%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $2.8B | $3.1B |
| 净利润 | $-103.0M | $181.1M |
| 毛利率 | — | — |
| 营业利润率 | 17.0% | 8.0% |
| 净利率 | -3.7% | 5.8% |
| 营收同比 | 9.3% | -1.6% |
| 净利润同比 | -205.1% | 16.5% |
| 每股收益（稀释后） | $-0.30 | $1.88 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收BHCJBHT
| Q4 25 | $2.8B | $3.1B | ||
| Q3 25 | $2.7B | $3.1B | ||
| Q2 25 | $2.5B | $2.9B | ||
| Q1 25 | $2.3B | $2.9B | ||
| Q4 24 | $2.6B | $3.1B | ||
| Q3 24 | $2.5B | $3.1B | ||
| Q2 24 | $2.4B | $2.9B | ||
| Q1 24 | $2.2B | $2.9B |
净利润BHCJBHT
| Q4 25 | $-103.0M | $181.1M | ||
| Q3 25 | $179.0M | $170.8M | ||
| Q2 25 | $148.0M | $128.6M | ||
| Q1 25 | $-58.0M | $117.7M | ||
| Q4 24 | $98.0M | $155.5M | ||
| Q3 24 | $-85.0M | $152.1M | ||
| Q2 24 | $10.0M | $135.9M | ||
| Q1 24 | $-64.0M | $127.5M |
营业利润率BHCJBHT
| Q4 25 | 17.0% | 8.0% | ||
| Q3 25 | 23.1% | 7.9% | ||
| Q2 25 | 17.5% | 6.7% | ||
| Q1 25 | 12.2% | 6.1% | ||
| Q4 24 | 21.8% | 6.6% | ||
| Q3 24 | 12.7% | 7.3% | ||
| Q2 24 | 16.2% | 7.0% | ||
| Q1 24 | 13.1% | 6.6% |
净利率BHCJBHT
| Q4 25 | -3.7% | 5.8% | ||
| Q3 25 | 6.7% | 5.6% | ||
| Q2 25 | 5.8% | 4.4% | ||
| Q1 25 | -2.6% | 4.0% | ||
| Q4 24 | 3.8% | 4.9% | ||
| Q3 24 | -3.4% | 5.0% | ||
| Q2 24 | 0.4% | 4.6% | ||
| Q1 24 | -3.0% | 4.3% |
每股收益（稀释后）BHCJBHT
| Q4 25 | $-0.30 | $1.88 | ||
| Q3 25 | $0.48 | $1.76 | ||
| Q2 25 | $0.40 | $1.31 | ||
| Q1 25 | $-0.16 | $1.17 | ||
| Q4 24 | $0.24 | $1.53 | ||
| Q3 24 | $-0.23 | $1.49 | ||
| Q2 24 | $0.03 | $1.32 | ||
| Q1 24 | $-0.17 | $1.22 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $1.3B | $17.3M |
| 总债务越低越好 | $20.8B | — |
| 股东权益账面价值 | $-554.0M | $3.6B |
| 总资产 | $26.4B | $7.9B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资BHCJBHT
| Q4 25 | $1.3B | $17.3M | ||
| Q3 25 | $1.3B | $52.3M | ||
| Q2 25 | $1.7B | $50.9M | ||
| Q1 25 | $1.1B | $43.4M | ||
| Q4 24 | $1.2B | $47.0M | ||
| Q3 24 | $719.0M | $120.0M | ||
| Q2 24 | $595.0M | $53.5M | ||
| Q1 24 | $733.0M | $64.2M |
总债务BHCJBHT
| Q4 25 | $20.8B | — | ||
| Q3 25 | $21.0B | — | ||
| Q2 25 | $21.7B | — | ||
| Q1 25 | $21.5B | — | ||
| Q4 24 | $21.6B | $977.7M | ||
| Q3 24 | $21.5B | $1.0B | ||
| Q2 24 | $21.7B | $1.5B | ||
| Q1 24 | $22.1B | $1.4B |
股东权益BHCJBHT
| Q4 25 | $-554.0M | $3.6B | ||
| Q3 25 | $-565.0M | $3.6B | ||
| Q2 25 | $-764.0M | $3.7B | ||
| Q1 25 | $-1.2B | $3.9B | ||
| Q4 24 | $-1.3B | $4.0B | ||
| Q3 24 | $-1.2B | $4.0B | ||
| Q2 24 | $-1.2B | $4.1B | ||
| Q1 24 | $-1.1B | $4.2B |
总资产BHCJBHT
| Q4 25 | $26.4B | $7.9B | ||
| Q3 25 | $26.8B | $8.1B | ||
| Q2 25 | $27.3B | $8.2B | ||
| Q1 25 | $26.4B | $8.3B | ||
| Q4 24 | $26.5B | $8.3B | ||
| Q3 24 | $26.5B | $8.3B | ||
| Q2 24 | $26.5B | $8.4B | ||
| Q1 24 | $26.9B | $8.4B |
负债/权益比BHCJBHT
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 0.24× | ||
| Q3 24 | — | 0.26× | ||
| Q2 24 | — | 0.36× | ||
| Q1 24 | — | 0.33× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $495.0M | $385.6M |
| 自由现金流经营现金流 - 资本支出 | $403.0M | $251.3M |
| 自由现金流率自由现金流/营收 | 14.4% | 8.1% |
| 资本支出强度资本支出/营收 | 3.3% | 4.3% |
| 现金转化率经营现金流/净利润 | — | 2.13× |
| 过去12个月自由现金流最近4个季度 | $1.0B | $947.6M |
8季度趋势，按日历期对齐
经营现金流BHCJBHT
| Q4 25 | $495.0M | $385.6M | ||
| Q3 25 | $405.0M | $486.4M | ||
| Q2 25 | $289.0M | $402.1M | ||
| Q1 25 | $211.0M | $404.2M | ||
| Q4 24 | $601.0M | $317.6M | ||
| Q3 24 | $405.0M | $338.5M | ||
| Q2 24 | $380.0M | $360.6M | ||
| Q1 24 | $211.0M | $466.5M |
自由现金流BHCJBHT
| Q4 25 | $403.0M | $251.3M | ||
| Q3 25 | $314.0M | $352.4M | ||
| Q2 25 | $190.0M | $185.6M | ||
| Q1 25 | $96.0M | $158.4M | ||
| Q4 24 | $495.0M | $93.3M | ||
| Q3 24 | $334.0M | $163.1M | ||
| Q2 24 | $302.0M | $98.2M | ||
| Q1 24 | $129.0M | $263.1M |
自由现金流率BHCJBHT
| Q4 25 | 14.4% | 8.1% | ||
| Q3 25 | 11.7% | 11.5% | ||
| Q2 25 | 7.5% | 6.3% | ||
| Q1 25 | 4.2% | 5.4% | ||
| Q4 24 | 19.3% | 3.0% | ||
| Q3 24 | 13.3% | 5.3% | ||
| Q2 24 | 12.6% | 3.4% | ||
| Q1 24 | 6.0% | 8.9% |
资本支出强度BHCJBHT
| Q4 25 | 3.3% | 4.3% | ||
| Q3 25 | 3.4% | 4.4% | ||
| Q2 25 | 3.9% | 7.4% | ||
| Q1 25 | 5.1% | 8.4% | ||
| Q4 24 | 4.1% | 7.1% | ||
| Q3 24 | 2.8% | 5.7% | ||
| Q2 24 | 3.2% | 9.0% | ||
| Q1 24 | 3.8% | 6.9% |
现金转化率BHCJBHT
| Q4 25 | — | 2.13× | ||
| Q3 25 | 2.26× | 2.85× | ||
| Q2 25 | 1.95× | 3.13× | ||
| Q1 25 | — | 3.43× | ||
| Q4 24 | 6.13× | 2.04× | ||
| Q3 24 | — | 2.23× | ||
| Q2 24 | 38.00× | 2.65× | ||
| Q1 24 | — | 3.66× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
BHC
| Bausch Lomb | $1.4B | 50% |
| Salix Segment | $693.0M | 25% |
| International Rx | $306.0M | 11% |
| Diversified Segment | $255.0M | 9% |
| Solta Medical Segment | $137.0M | 5% |
JBHT
| JBI | $1.5B | 50% |
| DCS | $842.8M | 27% |
| ICS | $304.5M | 10% |
| FMS | $206.3M | 7% |
| JBT | $200.7M | 6% |
